Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

NCT06839144 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

Ovarian Cancer
Ovarian Cancer Metastatic Recurrent

Interventions

DRUG: Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)
DRUG: Placebo (Matching for Propranolol & Etodolac)

Sponsor

Tel-Aviv Sourasky Medical Center

Collaborators

[object Object]
[object Object]